The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot study of pharmacokinetically guided dose management of capecitabine in CRC patients.
Katsuya Makihara
No relevant relationships to disclose
Hideyuki Mishima
No relevant relationships to disclose
Sayaka Azuma
No relevant relationships to disclose
Kazuyo Matsuyama
No relevant relationships to disclose
Katsuya Komori
No relevant relationships to disclose
Hiroko Hasegawa
No relevant relationships to disclose
Masayoshi Yasui
No relevant relationships to disclose
Masakazu Ikenaga
No relevant relationships to disclose
Toshimasa Tsujinaka
No relevant relationships to disclose